ABERA: Positive preclinical results and new funding drive clinical trial preparations and liquidity

About this update from Abera Bioscience Ab

Q2 2025 saw continued progress in vaccine development, with positive preclinical results and regulatory support for clinical trials. Financially, grant income and a successful share issue strengthened liquidity, while operating losses persisted. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Abera Bioscience Ab